4-(甲氧基甲基)-2-吡啶羧酸 | 354518-16-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 4-(甲氧基甲基)-2-吡啶羧酸
• 英文名称: 4-(methoxymethyl)picolinic acid
• 英文别名: 4-(Methoxymethyl)pyridine-2-carboxylic acid
• CAS: 354518-16-4
• 化学式: C₈H₉NO₃
• 分子量: 167.164
• InChiKey: UIUUZYJMNMXJEI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  59.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(甲氧基甲基)-2-吡啶羧酸 在 氯甲酸乙酯 、 三乙胺 、 sodium azide 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 3.0h， 生成
  参考文献：
  名称：

  Ouach, Aziz; Boulahjar, Rajâa; Vala, Christine, European Journal of Medicinal Chemistry, 2016, vol. 115, p. 311 - 325

  摘要：

  DOI：
• 作为产物：
  描述：

  methyl 4-methoxymethylpyridine-2-carboxylate 在 水 、 sodium hydroxide 作用下， 以 四氢呋喃 为溶剂， 以73%的产率得到4-(甲氧基甲基)-2-吡啶羧酸
  参考文献：
  名称：

  Ouach, Aziz; Boulahjar, Rajâa; Vala, Christine, European Journal of Medicinal Chemistry, 2016, vol. 115, p. 311 - 325

  摘要：

  DOI：

文献信息

• LONG-ACTING HIV PROTEASE INHIBITOR
  申请人：Shionogi & Co., Ltd.

  公开号：US20170253607A1

  公开（公告）日：2017-09-07

  The present invention provides useful compounds for HIV protease inhibitor. A compound represented by the following formula or its pharmaceutically acceptable salt: wherein ring A is R 4 is —Y—Z, hydrogen atom, halogen, hydroxy and the like, R 5 is hydrogen atom, halogen, hydroxy and the like, R 6 is each independently halogen, hydroxy, carboxy and the like, ring A may be substituted with said R 6 at any substitutable position(s), a is an integer of 0 to 7, ring B is substituted or unsubstituted aromatic carbocyclyl, or substituted or unsubstituted aromatic heterocyclyl, ring C is substituted or unsubstituted aromatic carbocyclyl, substituted or unsubstituted non-aromatic carbocyclyl, substituted or unsubstituted aromatic heterocyclyl, or substituted or unsubstituted non-aromatic heterocyclyl, R 1 is —Y—Z, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl and the like, R 2 and R 3 are each independently —Y—Z or hydrogen atom, provided that at least one of R 1 , R 2 , R 3 and R 4 is a group represented by formula: —Y—Z, Y is a bond, or a spacer of any combination selected from the group consisting of —O—, —S—, —NR 7 —, —C(═O)—, —SO—, —SO 2 —, —NR 7 —C(═O)—, —C(═O)—NR 7 —, —NR 7 —C(═O)—NR 7 —, —O—C(═O)—NR 7 —, —NR 7 —C(═O)—O—, —SO 2 —NR 7 —, —NR 7 —SO 2 —, substituted or unsubstituted alkylene, substituted or unsubstituted alkenylene, substituted or unsubstituted alkynylene, substituted or unsubstituted aromatic carbocyclediyl, substituted or unsubstituted non-aromatic carbocyclediyl, substituted or unsubstituted aromatic heterocyclediyl and substituted or unsubstituted non-aromatic heterocyclediyl, R 7 are each independently hydrogen atom, hydroxy, carboxy and the like, and Z is substituted aromatic carbocyclyl, substituted non-aromatic carbocyclyl, substituted aromatic heterocyclyl or substituted non-aromatic heterocyclyl.
• US8742123B2
  申请人：——

  公开号：US8742123B2

  公开（公告）日：2014-06-03
• Ouach, Aziz; Boulahjar, Rajâa; Vala, Christine, European Journal of Medicinal Chemistry, 2016, vol. 115, p. 311 - 325
  作者：Ouach, Aziz、Boulahjar, Rajâa、Vala, Christine、Bourg, Stéphane、Bonnet, Pascal、Guguen-Guillouzo, Christiane、Ravache, Myriam、Le Guevel, Rémy、Lozach, Olivier、Lazar, Saïd、Troin, Yves、Meijer, Laurent、Ruchaud, Sandrine、Akssira, Mohamed、Guillaumet, Gérald、Routier, Sylvain

  DOI：——

  日期：——